PDF
File
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
"We are ending 2023 with healthy growth, significantly improved earnings and strong operating cash flow. During the year considerable focus was put on profitable growth in a market characterized by stabilization and recovery. We are now continuing our efforts to further strengthen our positions during 2024 and beyond," says Joacim Lindoff, President and CEO of Arjo.
- Net sales increased to SEK 2,879 M (2,686).
- Adjusted EBITDA increased 27.6% to SEK 614 M (481).
- Adjusted operating profit increased 52.4% to SEK 342 M (224).
- Profit after financial items increased to SEK 242 M (133).
- Earnings per share rose to SEK 0.67 (0.37).
- Cash flow from operations rose to SEK 734 M (425), corresponding to a cash conversion of 124.6% (99.4).
- A dividend per share of SEK 0.90 (0.85) is proposed, corresponding to approximately SEK 245 M.
Telephone conference
Fund managers, analysts and media are invited to participate in a conference call and presentation of the report on January 30 at 08.00 CET via the following link: https://ir.financialhearings.com/arjo-q4-report-2023
Those who wish to ask questions verbally during the teleconference will need to register via the link below. A phone number and a conference ID will be provided after registration in order to access the conference. Link to registration: https://conference.financialhearings.com/teleconference/?id=5001443
Alternatively, use the following link to download the presentation:
https://www.arjo.com/int/about-us/investors/reports--presentations/2024/
A recorded version of the conference is accessible for three years via the following link:
https://ir.financialhearings.com/arjo-q4-report-2023
For more information, please contact:
Maria Nilsson, EVP Communications & Public Relations
Tel: +46 734 244 515
Email: maria.nilsson@arjo.com
Sara Ehinger, VP Investor Relations & Corporate Communications
Tel: +46 723 597 794
Email: sara.ehinger@arjo.com
This information is information that Arjo AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 07:00 CET on January 30, 2024.
About Arjo
At Arjo, we believe that empowering movement within healthcare environments is essential to quality care. Our products and solutions are designed to promote a safe and dignified experience through patient handling, medical beds, personal hygiene, disinfection, diagnostics, and the prevention of pressure injuries and venous thromboembolism. With more than 6,500 people worldwide and over 65 years caring for patients and healthcare professionals, we are committed to driving healthier outcomes for people facing mobility challenges. www.arjo.com